Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies.
Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies.
复制标题
DOI：
10.3390/diagnostics11020351
复制
发表时间：
2021-02-20
期刊：
影响因子：
--
通讯作者：
Longo N
中科院分区：
文献类型：
--
作者：
Creta M;Celentano G;Napolitano L;La Rocca R;Capece M;Califano G;Collà Ruvolo C;Mangiapia F;Morra S;Turco C;Spirito L;Fusco F;Imbimbo C;Mirone V;Longo N
膀胱癌（BCa）是一种内分泌相关肿瘤，雄激素信号通路的激活可能促进膀胱肿瘤的发生。我们总结了雄激素信号通路对BCa治疗结果影响的临床前和临床证据。2020年12月进行了系统审查。我们纳入了符合以下标准的论文：原始的临床前和临床研究；评估雄激素信号调节对BCa治疗结果的影响。确定了6项临床前研究和8项临床研究。临床前证据表明，雄激素受体相关通路的调节有可能干扰卡介苗、阿霉素、顺铂、吉西他滨和放疗的活性。接受5- α还原酶抑制剂（5- aris）或雄激素剥夺治疗（ADT）的患者经尿道膀胱肿瘤切除术（TURBT）后BCa复发的相对风险显著降低（相对风险：0.50,95% CI: 0.30-0.82; p = 0.006）。接受5-ARIs治疗的患者的亚组分析显示BCa复发的相对风险为0.46 （95% CI: 0.22-0.95; p = 0.040）。治疗组/对照组T1 BCa患者的比例与BCa复发的相对风险呈显著负相关。5-ARIs治疗可能是一种潜在的策略，旨在降低BCa复发率，主要用于低期疾病患者。需要进一步的研究来证实这些初步数据。
Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.
登录
查看更多内容
DOI：
10.4103/iju.iju_320_19
发表时间：
2020-07
期刊：
Indian journal of urology : IJU : journal of the Urological Society of India
影响因子：
--
作者：
Moorthy HK;Prabhu GGL;Venugopal P
通讯作者：
Venugopal P
影响因子：
5.7
作者：
Shang Z;Li Y;Zhang M;Tian J;Han R;Shyr CR;Messing E;Yeh S;Niu Y;Chang C
通讯作者：
Chang C
影响因子：
2.1
作者：
Boorjian, S;Ugras, S;Scherr, DS
通讯作者：
Scherr, DS
影响因子：
5.7
作者：
Mizushima, Taichi;Jiang, Guiyang;Miyamoto, Hiroshi
通讯作者：
Miyamoto, Hiroshi
影响因子：
5.7
作者：
Ide, Hiroki;Inoue, Satoshi;Miyamoto, Hiroshi
通讯作者：
Miyamoto, Hiroshi